Aprea Therapeutics (NASDAQ:APRE) is a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Aprea is driven by a commitment to advance science and improve the lives of patients suffering from various types of cancer. Its flagship project, the p53 reactivator, represents a breakthrough approach in cancer treatment, targeting one of the most common mutations in cancer to restore the function of the p53 protein, often referred to as the "guardian of the genome" due to its role in controlling cell division and preventing tumor growth. The company's objectives include progressing its pipeline through clinical trials to commercialization, with a keen focus on safety, efficacy, and accessibility for cancer patients globally.